221 related articles for article (PubMed ID: 31100455)
21. Pattern of esophageal eosinophilic infiltration in patients with achalasia and response to Heller myotomy and Dor fundoplication.
Cools-Lartigue J; Chang SY; Mckendy K; Mayrand S; Marcus V; Fried GM; Ferri LE
Dis Esophagus; 2013; 26(8):766-75. PubMed ID: 22891632
[TBL] [Abstract][Full Text] [Related]
22. Specific epicutaneous immunotherapy prevents sensitization to new allergens in a murine model.
Mondoulet L; Dioszeghy V; Puteaux E; Ligouis M; Dhelft V; Plaquet C; Dupont C; Benhamou PH
J Allergy Clin Immunol; 2015 Jun; 135(6):1546-57.e4. PubMed ID: 25583102
[TBL] [Abstract][Full Text] [Related]
23. Effects of allergen sensitization on response to therapy in children with eosinophilic esophagitis.
Pesek RD; Rettiganti M; O'Brien E; Beckwith S; Daniel C; Luo C; Scurlock AM; Chandler P; Levy RA; Perry TT; Kennedy JL; Chervinskiy S; Vonlanthen M; Casteel H; Fiedorek SC; Gibbons T; Jones SM
Ann Allergy Asthma Immunol; 2017 Aug; 119(2):177-183. PubMed ID: 28676207
[TBL] [Abstract][Full Text] [Related]
24. Baseline Gastrointestinal Eosinophilia Is Common in Oral Immunotherapy Subjects With IgE-Mediated Peanut Allergy.
Wright BL; Fernandez-Becker NQ; Kambham N; Purington N; Tupa D; Zhang W; Rank MA; Kita H; Shim KP; Bunning BJ; Doyle AD; Jacobsen EA; Boyd SD; Tsai M; Maecker H; Manohar M; Galli SJ; Nadeau KC; Chinthrajah RS
Front Immunol; 2018; 9():2624. PubMed ID: 30524424
[No Abstract] [Full Text] [Related]
25. Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis.
Gupta SK; Vitanza JM; Collins MH
Clin Gastroenterol Hepatol; 2015 Jan; 13(1):66-76.e3. PubMed ID: 24907502
[TBL] [Abstract][Full Text] [Related]
26. Pooled Phase 2 and 3 Efficacy and Safety Data on Budesonide Oral Suspension in Adolescents with Eosinophilic Esophagitis.
Mukkada VA; Gupta SK; Gold BD; Dellon ES; Collins MH; Katzka DA; Falk GW; Williams J; Zhang W; Boules M; Hirano I; Desai NK
J Pediatr Gastroenterol Nutr; 2023 Dec; 77(6):760-768. PubMed ID: 37718471
[TBL] [Abstract][Full Text] [Related]
27. STAT6 Variants Associate With Relapse of Eosinophilic Esophagitis in Patients Receiving Long-term Proton Pump Inhibitor Therapy.
Mougey EB; Nguyen V; Gutiérrez-Junquera C; Fernández-Fernández S; Cilleruelo ML; Rayo A; Borrell B; Román E; González-Lois C; Chao M; Al-Atrash H; Franciosi JP
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2046-2053.e2. PubMed ID: 32798708
[TBL] [Abstract][Full Text] [Related]
28. RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.
Hirano I; Collins MH; Assouline-Dayan Y; Evans L; Gupta S; Schoepfer AM; Straumann A; Safroneeva E; Grimm M; Smith H; Tompkins CA; Woo A; Peach R; Frohna P; Gujrathi S; Penenberg DN; Li C; Opiteck GJ; Olson A; Aranda R; Rothenberg ME; Dellon ES;
Gastroenterology; 2019 Feb; 156(3):592-603.e10. PubMed ID: 30395812
[TBL] [Abstract][Full Text] [Related]
29. Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE.
Clayton F; Fang JC; Gleich GJ; Lucendo AJ; Olalla JM; Vinson LA; Lowichik A; Chen X; Emerson L; Cox K; O'Gorman MA; Peterson KA
Gastroenterology; 2014 Sep; 147(3):602-9. PubMed ID: 24907494
[TBL] [Abstract][Full Text] [Related]
30. Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis.
Dellon ES; Katzka DA; Collins MH; Hamdani M; Gupta SK; Hirano I;
Gastroenterology; 2017 Mar; 152(4):776-786.e5. PubMed ID: 27889574
[TBL] [Abstract][Full Text] [Related]
31. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis.
Straumann A; Hoesli S; Bussmann Ch; Stuck M; Perkins M; Collins LP; Payton M; Pettipher R; Hunter M; Steiner J; Simon HU
Allergy; 2013 Mar; 68(3):375-85. PubMed ID: 23379537
[TBL] [Abstract][Full Text] [Related]
32. Swallowed Fluticasone Propionate Is an Effective Long-Term Maintenance Therapy for Children With Eosinophilic Esophagitis.
Andreae DA; Hanna MG; Magid MS; Malerba S; Andreae MH; Bagiella E; Chehade M
Am J Gastroenterol; 2016 Aug; 111(8):1187-97. PubMed ID: 27325220
[TBL] [Abstract][Full Text] [Related]
33. Endoscopic and histological characteristics in patients with eosinophilic esophagitis responsive and non-responsive to proton pump inhibitors.
Vieira GG; Ribeiro LBM; Truppel SK; Rosário Filho NA; Vieira MC
J Pediatr (Rio J); 2020; 96(5):638-643. PubMed ID: 31361987
[TBL] [Abstract][Full Text] [Related]
34. Image Analysis of Eosinophil Peroxidase Immunohistochemistry for Diagnosis of Eosinophilic Esophagitis.
Wright BL; Doyle AD; Shim KP; Pai RK; Barshow SM; Horsley-Silva JL; Luo H; Rank MA; Jacobsen EA; Katzka DA; Kita H; Dellon ES
Dig Dis Sci; 2021 Mar; 66(3):775-783. PubMed ID: 32248390
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial.
Lucendo AJ; Miehlke S; Schlag C; Vieth M; von Arnim U; Molina-Infante J; Hartmann D; Bredenoord AJ; Ciriza de Los Rios C; Schubert S; Brückner S; Madisch A; Hayat J; Tack J; Attwood S; Mueller R; Greinwald R; Schoepfer A; Straumann A;
Gastroenterology; 2019 Jul; 157(1):74-86.e15. PubMed ID: 30922997
[TBL] [Abstract][Full Text] [Related]
36. Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis.
van Rhijn BD; Weijenborg PW; Verheij J; van den Bergh Weerman MA; Verseijden C; van den Wijngaard RM; de Jonge WJ; Smout AJ; Bredenoord AJ
Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1815-23.e2. PubMed ID: 24657840
[TBL] [Abstract][Full Text] [Related]
37. Impedance and Histologic Characteristics of the Sub-Laryngeal Esophagus Distinguish Eosinophilic Esophagitis From Other Esophageal Disorders.
Choksi YA; Chaparro J; Blanco M; Sharda R; Sarker S; Ferguson S; Higginbotham T; Hiremath G; Revetta F; Washington MK; Williams CS; Vaezi MF
Clin Gastroenterol Hepatol; 2020 Jul; 18(8):1727-1735.e2. PubMed ID: 31589979
[TBL] [Abstract][Full Text] [Related]
38. Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6-week open-label trial of the EOS-2 Programme.
Miehlke S; Schlag C; Lucendo AJ; Biedermann L; Vaquero CS; Schmoecker C; Hayat J; Hruz P; Ciriza de Los Rios C; Bredenoord AJ; Vieth M; Schoepfer A; Attwood S; Mueller R; Burrack S; Greinwald R; Straumann A;
United European Gastroenterol J; 2022 Apr; 10(3):330-343. PubMed ID: 35412032
[TBL] [Abstract][Full Text] [Related]
39. Number of bottles of esophageal biopsies in the evaluation of eosinophilic esophagitis and clinical outcomes.
Koop AH; Middleton J; Travers PM; Ghoz H; Francis D; DeVault KR; Pang M
Clin Res Hepatol Gastroenterol; 2023 Aug; 47(7):102142. PubMed ID: 37263347
[TBL] [Abstract][Full Text] [Related]
40. Eosinophilic esophagitis in children under the age of 5 years: Clinical characteristics.
Sun RW; Bonilla-Velez J; Pesek RD; Johnson AB; Cleves MA; Richter GT
Laryngoscope; 2018 Apr; 128(4):798-805. PubMed ID: 28865084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
